Which cells?

Find out more about Axiogenesis products and possible applications.

>>> Learn more

Which service?

Discover Axiogenesis' highly specialized in-house services. 

>>> Learn more

Which application?

How to apply Axiogenesis products to your research and development needs.

 >>> Learn more

human iPS-derived in vitro differentiated cardiomyocytes

Axiogenesis AG at a glance

Axiogenesis AG is a pioneer of murine embryonic stem cell technology and the world leader in murine stem cell-derived products. Its proprietary production technology enables the commercialization of pure in vitro differentiated cardiomyocytes (Cor.At®), smooth muscle cells (Smac.4M®) and endothelial cells (Endo.4M®) of outstanding product quality (preparation purity, freeze-thaw stability, lot-to-lot uniformity). 

Axiogenesis are the first to patent a disease model for cardiac hypertrophy, a disease affecting  many millions in the US and Europe alone. Until now, drug developement has been hindered by the lack of a usable in vitro disease model. Axiogenesis' in vitro differentiated cardiomyocytes can be made to display a diseased phenotype, which opens up a whole spectrum of opportunities for drug development.

Axiogenesis AG offers a unique service portfolio, from which Cor.At cardiomyocytes evolved as the gold standard tool for in vitro cardiac toxicology and drug discovery. It provides assays for experiments in electrophysiology, toxicology, cytotoxity, embryotoxicity and a uniquein vitro disease model for cardiac hypertrophy.

Currently, Axiogenesis is expanding its portfolio through the induced pluripotent stem cell (iPS) technology by introducing murine IPS based products and services in addition to the ES based product family. The service Cor.4U-MEA® introduces human cardiomyocytes obtained from iPS cells on multi-electrode arrays for cardiac safety pharmacology testing, to be followed by additional products and service lines .

CM-Clinical Modeling® is Axiogenesis’ screening platform concept currently under development to support in-house drug discovery. Stem cell-derived tissues (heart, liver, neuron etc.) modulate specific pathological scenarios highly relevant for identification and stratification of new active pharmaceutical ingredients. Axiogenesis’ proprietary hypertrophy platform will fill pharma pipelines for future cardiomyopathy therapy.

 

 

 


In vitro differentiated cardiomyocytes and other cells are a big step forward in the quest for cheaper, more reliable and ethically acceptable methods for testing chemical compounds. This advance is amplified by the advent of induced pluripotent stem (iPS) cells that allow the generation of human in vitro cell cultures without the legal constraints imposed on the use of human embryonic stem cells in most countries.

In vitro cell based assays, especially those using human cells, open up new horizons for establishing disease models for testing in the drug discovery process.